![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercepharma.com/manufacturing/surge-sales-biosimilars-helps-samsung-biologics-record-setting-quarter
https://www.globenewswire.com/news-release/2024/07/22/2916428/0/en/FDA-Approves-Samsung-Bioepis-EPYSQLI-eculizumab-aagh-as-a-Biosimilar-to-Soliris-eculizumab.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761340
https://www.fiercepharma.com/pharma/shrinking-market-share-abbvies-humira-loses-ground-battle-against-biosimilars-report
https://www.globenewswire.com/news-release/2024/07/11/2911765/0/en/Samsung-Bioepis-Releases-Third-Quarter-2024-US-Biosimilar-Market-Report.html
https://www.globenewswire.com/news-release/2024/07/01/2906408/0/en/FDA-Approves-PYZCHIVA-ustekinumab-ttwe-Samsung-Bioepis-Biosimilar-to-Stelara.html
https://www.contractpharma.com/contents/view_breaking-news/2024-07-02/samsung-bioepis-pyzchiva-approved-by-fda-as-biosimilar-of-stelara/?widget=listSection
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761425
https://www.globenewswire.com/news-release/2024/06/25/2903825/0/en/Samsung-Bioepis-Releases-2024-Sustainability-Report-Highlighting-Progress-in-Accessibility-and-R-D-Innovation.html
https://www.globenewswire.com/news-release/2024/06/14/2898787/0/en/Samsung-Bioepis-Presents-Post-hoc-Analysis-of-Phase-3-Study-for-EPYSQLI-SB12-Eculizumab-Biosimilar-at-the-European-Hematology-Association-EHA-Congress-2024.html